Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
26
MDXH Quote, Financials, Valuation and Earnings
Last price:
$3.6000
Seasonality move
:
-2.36%
Day range:
$3.3500 - $3.6000
52-week range:
$1.3500 - $5.3300
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
1.71x
P/B ratio:
23.64x
Volume:
144K
Avg. volume:
133.5K
1-year change:
50.63%
Market cap:
$176.7M
Revenue:
$90M
EPS (TTM):
-$0.64
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
MDXH
MDxHealth SA
|
$30.8M | -$0.26 | 24.39% | -35.9% | $7.0400 |
|
FONR
FONAR Corp.
|
-- | -- | -- | -- | -- |
|
ICLR
ICON plc
|
$2B | $3.32 | -1.45% | 5% | $206.38 |
|
PRPH
ProPhase Labs, Inc.
|
$3.6M | -$0.15 | 3.99% | -50% | $13.80 |
|
VCYT
Veracyte, Inc.
|
$131.7M | $0.39 | 11.04% | 511.28% | $47.50 |
|
XWEL
XWELL, Inc.
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
MDXH
MDxHealth SA
|
$3.5700 | $7.0400 | $176.7M | -- | $0.00 | 0% | 1.71x |
|
FONR
FONAR Corp.
|
$18.56 | -- | $116.9M | 16.78x | $0.00 | 0% | 1.13x |
|
ICLR
ICON plc
|
$182.22 | $206.38 | $13.9B | 24.63x | $0.00 | 0% | 1.80x |
|
PRPH
ProPhase Labs, Inc.
|
$0.45 | $13.80 | $1.9M | -- | $0.00 | 0% | 0.31x |
|
VCYT
Veracyte, Inc.
|
$42.10 | $47.50 | $3.3B | 110.91x | $0.00 | 0% | 6.76x |
|
XWEL
XWELL, Inc.
|
$0.46 | -- | $2.7M | -- | $0.00 | 0% | 0.08x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
MDXH
MDxHealth SA
|
110.38% | 3.283 | 38.19% | 0.98x |
|
FONR
FONAR Corp.
|
18.59% | 1.184 | 49.09% | 9.64x |
|
ICLR
ICON plc
|
27.67% | 0.618 | 26.73% | 0.98x |
|
PRPH
ProPhase Labs, Inc.
|
52.83% | 0.697 | 40.4% | 0.07x |
|
VCYT
Veracyte, Inc.
|
3.12% | 1.309 | 1.49% | 5.74x |
|
XWEL
XWELL, Inc.
|
278.04% | 2.325 | 65.46% | 0.57x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
MDXH
MDxHealth SA
|
$16.6M | -$3.5M | -39.3% | -548.42% | -12.67% | -$1M |
|
FONR
FONAR Corp.
|
$10.4M | $3.2M | 4.68% | 5.84% | 12.26% | -$636K |
|
ICLR
ICON plc
|
$456M | $258.9M | 4.57% | 6.29% | 12.67% | $351.9M |
|
PRPH
ProPhase Labs, Inc.
|
-$650.5K | -$4.8M | -51.85% | -90.24% | -539.52% | -$3.5M |
|
VCYT
Veracyte, Inc.
|
$89.4M | $23.1M | 2.43% | 2.52% | 17.53% | $42M |
|
XWEL
XWELL, Inc.
|
$1.3M | -$282K | -84.75% | -224.93% | -3.84% | -$3.1M |
MDxHealth SA vs. Competitors
-
Which has Higher Returns MDXH or FONR?
FONAR Corp. has a net margin of -29.2% compared to MDxHealth SA's net margin of 10.25%. MDxHealth SA's return on equity of -548.42% beat FONAR Corp.'s return on equity of 5.84%.
Company Gross Margin Earnings Per Share Invested Capital MDXHMDxHealth SA60.43% -$0.16 $79.6M FONRFONAR Corp.40.11% $0.34 $201.3M -
What do Analysts Say About MDXH or FONR?
MDxHealth SA has a consensus price target of $7.0400, signalling upside risk potential of 97.2%. On the other hand FONAR Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that MDxHealth SA has higher upside potential than FONAR Corp., analysts believe MDxHealth SA is more attractive than FONAR Corp..
Company Buy Ratings Hold Ratings Sell Ratings MDXHMDxHealth SA6 0 0 FONRFONAR Corp.0 0 0 -
Is MDXH or FONR More Risky?
MDxHealth SA has a beta of -556,299.560, which suggesting that the stock is 55630055.981% less volatile than S&P 500. In comparison FONAR Corp. has a beta of 0.993, suggesting its less volatile than the S&P 500 by 0.67700000000001%.
-
Which is a Better Dividend Stock MDXH or FONR?
MDxHealth SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. FONAR Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MDxHealth SA pays -- of its earnings as a dividend. FONAR Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDXH or FONR?
MDxHealth SA quarterly revenues are $27.4M, which are larger than FONAR Corp. quarterly revenues of $26M. MDxHealth SA's net income of -$8M is lower than FONAR Corp.'s net income of $2.7M. Notably, MDxHealth SA's price-to-earnings ratio is -- while FONAR Corp.'s PE ratio is 16.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MDxHealth SA is 1.71x versus 1.13x for FONAR Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDXHMDxHealth SA1.71x -- $27.4M -$8M FONRFONAR Corp.1.13x 16.78x $26M $2.7M
-
Which has Higher Returns MDXH or ICLR?
ICON plc has a net margin of -29.2% compared to MDxHealth SA's net margin of 0.12%. MDxHealth SA's return on equity of -548.42% beat ICON plc's return on equity of 6.29%.
Company Gross Margin Earnings Per Share Invested Capital MDXHMDxHealth SA60.43% -$0.16 $79.6M ICLRICON plc22.32% $0.03 $12.9B -
What do Analysts Say About MDXH or ICLR?
MDxHealth SA has a consensus price target of $7.0400, signalling upside risk potential of 97.2%. On the other hand ICON plc has an analysts' consensus of $206.38 which suggests that it could grow by 13.26%. Given that MDxHealth SA has higher upside potential than ICON plc, analysts believe MDxHealth SA is more attractive than ICON plc.
Company Buy Ratings Hold Ratings Sell Ratings MDXHMDxHealth SA6 0 0 ICLRICON plc10 8 0 -
Is MDXH or ICLR More Risky?
MDxHealth SA has a beta of -556,299.560, which suggesting that the stock is 55630055.981% less volatile than S&P 500. In comparison ICON plc has a beta of 1.256, suggesting its more volatile than the S&P 500 by 25.574%.
-
Which is a Better Dividend Stock MDXH or ICLR?
MDxHealth SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ICON plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MDxHealth SA pays -- of its earnings as a dividend. ICON plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDXH or ICLR?
MDxHealth SA quarterly revenues are $27.4M, which are smaller than ICON plc quarterly revenues of $2B. MDxHealth SA's net income of -$8M is lower than ICON plc's net income of $2.4M. Notably, MDxHealth SA's price-to-earnings ratio is -- while ICON plc's PE ratio is 24.63x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MDxHealth SA is 1.71x versus 1.80x for ICON plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDXHMDxHealth SA1.71x -- $27.4M -$8M ICLRICON plc1.80x 24.63x $2B $2.4M
-
Which has Higher Returns MDXH or PRPH?
ProPhase Labs, Inc. has a net margin of -29.2% compared to MDxHealth SA's net margin of -774.52%. MDxHealth SA's return on equity of -548.42% beat ProPhase Labs, Inc.'s return on equity of -90.24%.
Company Gross Margin Earnings Per Share Invested Capital MDXHMDxHealth SA60.43% -$0.16 $79.6M PRPHProPhase Labs, Inc.-73.67% -$1.65 $14.5M -
What do Analysts Say About MDXH or PRPH?
MDxHealth SA has a consensus price target of $7.0400, signalling upside risk potential of 97.2%. On the other hand ProPhase Labs, Inc. has an analysts' consensus of $13.80 which suggests that it could grow by 30737.99%. Given that ProPhase Labs, Inc. has higher upside potential than MDxHealth SA, analysts believe ProPhase Labs, Inc. is more attractive than MDxHealth SA.
Company Buy Ratings Hold Ratings Sell Ratings MDXHMDxHealth SA6 0 0 PRPHProPhase Labs, Inc.0 0 0 -
Is MDXH or PRPH More Risky?
MDxHealth SA has a beta of -556,299.560, which suggesting that the stock is 55630055.981% less volatile than S&P 500. In comparison ProPhase Labs, Inc. has a beta of -0.559, suggesting its less volatile than the S&P 500 by 155.946%.
-
Which is a Better Dividend Stock MDXH or PRPH?
MDxHealth SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ProPhase Labs, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MDxHealth SA pays -- of its earnings as a dividend. ProPhase Labs, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDXH or PRPH?
MDxHealth SA quarterly revenues are $27.4M, which are larger than ProPhase Labs, Inc. quarterly revenues of $883K. MDxHealth SA's net income of -$8M is lower than ProPhase Labs, Inc.'s net income of -$6.8M. Notably, MDxHealth SA's price-to-earnings ratio is -- while ProPhase Labs, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MDxHealth SA is 1.71x versus 0.31x for ProPhase Labs, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDXHMDxHealth SA1.71x -- $27.4M -$8M PRPHProPhase Labs, Inc.0.31x -- $883K -$6.8M
-
Which has Higher Returns MDXH or VCYT?
Veracyte, Inc. has a net margin of -29.2% compared to MDxHealth SA's net margin of 14.51%. MDxHealth SA's return on equity of -548.42% beat Veracyte, Inc.'s return on equity of 2.52%.
Company Gross Margin Earnings Per Share Invested Capital MDXHMDxHealth SA60.43% -$0.16 $79.6M VCYTVeracyte, Inc.67.76% $0.24 $1.3B -
What do Analysts Say About MDXH or VCYT?
MDxHealth SA has a consensus price target of $7.0400, signalling upside risk potential of 97.2%. On the other hand Veracyte, Inc. has an analysts' consensus of $47.50 which suggests that it could grow by 12.83%. Given that MDxHealth SA has higher upside potential than Veracyte, Inc., analysts believe MDxHealth SA is more attractive than Veracyte, Inc..
Company Buy Ratings Hold Ratings Sell Ratings MDXHMDxHealth SA6 0 0 VCYTVeracyte, Inc.8 2 1 -
Is MDXH or VCYT More Risky?
MDxHealth SA has a beta of -556,299.560, which suggesting that the stock is 55630055.981% less volatile than S&P 500. In comparison Veracyte, Inc. has a beta of 1.876, suggesting its more volatile than the S&P 500 by 87.569%.
-
Which is a Better Dividend Stock MDXH or VCYT?
MDxHealth SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Veracyte, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MDxHealth SA pays -- of its earnings as a dividend. Veracyte, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDXH or VCYT?
MDxHealth SA quarterly revenues are $27.4M, which are smaller than Veracyte, Inc. quarterly revenues of $131.9M. MDxHealth SA's net income of -$8M is lower than Veracyte, Inc.'s net income of $19.1M. Notably, MDxHealth SA's price-to-earnings ratio is -- while Veracyte, Inc.'s PE ratio is 110.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MDxHealth SA is 1.71x versus 6.76x for Veracyte, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDXHMDxHealth SA1.71x -- $27.4M -$8M VCYTVeracyte, Inc.6.76x 110.91x $131.9M $19.1M
-
Which has Higher Returns MDXH or XWEL?
XWELL, Inc. has a net margin of -29.2% compared to MDxHealth SA's net margin of -2.87%. MDxHealth SA's return on equity of -548.42% beat XWELL, Inc.'s return on equity of -224.93%.
Company Gross Margin Earnings Per Share Invested Capital MDXHMDxHealth SA60.43% -$0.16 $79.6M XWELXWELL, Inc.17.32% -$0.26 $13M -
What do Analysts Say About MDXH or XWEL?
MDxHealth SA has a consensus price target of $7.0400, signalling upside risk potential of 97.2%. On the other hand XWELL, Inc. has an analysts' consensus of -- which suggests that it could grow by 1419.1%. Given that XWELL, Inc. has higher upside potential than MDxHealth SA, analysts believe XWELL, Inc. is more attractive than MDxHealth SA.
Company Buy Ratings Hold Ratings Sell Ratings MDXHMDxHealth SA6 0 0 XWELXWELL, Inc.0 0 0 -
Is MDXH or XWEL More Risky?
MDxHealth SA has a beta of -556,299.560, which suggesting that the stock is 55630055.981% less volatile than S&P 500. In comparison XWELL, Inc. has a beta of 1.326, suggesting its more volatile than the S&P 500 by 32.585%.
-
Which is a Better Dividend Stock MDXH or XWEL?
MDxHealth SA has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. XWELL, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. MDxHealth SA pays -- of its earnings as a dividend. XWELL, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios MDXH or XWEL?
MDxHealth SA quarterly revenues are $27.4M, which are larger than XWELL, Inc. quarterly revenues of $7.3M. MDxHealth SA's net income of -$8M is lower than XWELL, Inc.'s net income of -$211K. Notably, MDxHealth SA's price-to-earnings ratio is -- while XWELL, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for MDxHealth SA is 1.71x versus 0.08x for XWELL, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income MDXHMDxHealth SA1.71x -- $27.4M -$8M XWELXWELL, Inc.0.08x -- $7.3M -$211K
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Buy
81
ZIJMY alert for Jan 1
Zijin Mining Group Co., Ltd. [ZIJMY] is up 1.86% over the past day.
